Compare · NVS vs PRAX
NVS vs PRAX
Side-by-side comparison of Novartis AG (NVS) and Praxis Precision Medicines Inc. (PRAX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and PRAX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $279.39B, about 39.6x PRAX ($7.06B).
- Over the past year, NVS is up 24.1% and PRAX is up 471.3% - PRAX leads by 447.2 points.
- PRAX has hit the wire 9 times in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 17 for PRAX).
- Company
- Novartis AG
- Praxis Precision Medicines Inc.
- Price
- $146.50-1.72%
- $253.44-0.21%
- Market cap
- $279.39B
- $7.06B
- 1M return
- +0.71%
- -23.96%
- 1Y return
- +24.12%
- +471.33%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 9
- Recent ratings
- 25
- 17
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Praxis Precision Medicines Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
- Citigroup initiated coverage on Novartis AG
Latest PRAX
- Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Praxis Precision Medicines Inc. filed SEC Form 8-K: Other Events
- Praxis Precision Medicines Provides Vormatrigine Program Update
- Principal Accounting Officer Mastrocola Lauren was granted 127 shares, increasing direct ownership by 0.94% to 13,573 units (SEC Form 4)
- General Counsel and Secretary Nemiroff Alex was granted 78 shares, increasing direct ownership by 0.30% to 26,011 units (SEC Form 4)
- Chief Financial Officer Kelly Timothy Edwin was granted 121 shares, increasing direct ownership by 0.39% to 31,167 units (SEC Form 4)
- Chief Operating Officer Sniecinski Megan was granted 89 shares, increasing direct ownership by 0.31% to 28,664 units (SEC Form 4)
- Chief Executive Officer Souza Marcio was granted 126 shares, increasing direct ownership by 0.16% to 77,016 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Praxis Precision Medicines Inc.